The three major components of pathological scar prevention in the months following wound closure are prevention of tension, hydration/occlusion and compression.
Wounds where the maximum tension is exerted are wounds with edges placed under stress as well as wounds located in the deltoid and pre-sternal region. For scars located in areas of tension, it is recommended applying adhesive strips or tapes along the scar for three months after complete healing. Thin hydrocolloid dressings (which are more adherent) can be used as an alternative in children.
Using emollients and maintaining moisture through silicone strips or gels are recommended, as well as the use of sunscreen (factor 50+) or mechanical protection (clothing, dressings), until the scar has matured, which usually takesone year.
Compression through the use of customised clothing should be reserved for the initial phase of extensive scarring, particularly in burn patients, and should be prescribed by specialists.
It is recommended reassessing patients between 4-8 weeks after an acute wound (trauma or surgery) and between 6 weeks and 3 months for hypertrophic-scar patients, to allow them to benefit from medical compression devices and, if these devices are insufficient, to receive an injection of corticosteroids into the scar.
1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341: 738-46.
2. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol2007; 127: 514-25.
3. Suivi en ville des plaies chroniques : ulcère veineux de jambe, escarre, plaie du pied diabétique. Assurance maladie, octobre 2015.
4. Plaies aiguës en structure d’urgence. Référentiel de bonnes pratiques. SFMU, 2017: 32 p.
5. Sgonc R, Gruber J. Age-related aspects of cutaneous wound hea- ling: a mini-review. Gerontology 2013; 59: 159-64.
6. Majtan J. Honey: an immunomodulator in wound healing. Wound Repair Regen 2014; 22: 187-92.
7. Opletalová K, BlaizotX, Mourgeon B, et al. Maggot therapyfor wound debridement: a randomized multicenter trial. Arch Dermatol 2012; 148: 432-8.
8. van den Broek LJ, Limandjaja GC, Niessen FB, Gibbs S. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissueengineering perspective. ExpDer- matol 2014; 23: 382-6.
9. Prise en charge de l’ulcère de jambe à prédominance veineuse hors pansement. Recommandations HAS, 2006.
10. La compression médicale dans les affections veineuses chroniques. Fiche de bon usage HAS, 2010.
11. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, et al. Sucrose octasulfate dressing versus control dressing in patients with neu- roischaemic diabetic foot ulcers (Explorer): an international, multi- centre, double-blind, randomised, controlled trial [published correction appears in Lancet Diabetes Endocrinol 2018]. Lancet Diabetes Endocrinol 2018; 6: 186-96.
12. Reinholz M, Poetschke J, Schwaiger H, Epple A, Ruzicka T, Gauglitz GG. The dermatology life quality index as a means to assess life quality in patients with different scar types. J Eur Acad Dermatol Venereol 2015; 29: 2112-9.